European Archives - Page 701 of 1063 - European Medical Journal

The First Whole-Body Scanner Has Been Revealed

Explorer, the world’s first entire-body three-dimensional scanner was unveiled at the Radiological Society of North America (RSNA) meeting in November…

Nanostructures Shield the Kidneys from Oxidative Stress

“This represents a new horizon for DNA nanotechnology research,” announced Dr Hao Yan, University of Wisconsin-Madison, Madison, Wisconsin, USA, upon…

"Reputation is earned slowly and is based on not only what you do but how you do it"

We spoke to Dmitry at the eyeforpharma Marketing and Customer Innovation Conference, Europe 2018, on Russia’s rising presence within the pharma industry…

European Medical Journal Presents: EMJ Oncology 6.1

EMJ Oncology 6.1 is now available, presenting a full review of the European Society for Medical Oncology (ESMO) Congress 2018

Review of the European Society of Medical Oncology Congress 2018

Representing an essential platform for collective discussions on this year’s theme of ‘securing access to optimal cancer care’, the European Society for…

EMJ Oncology 6.1 2018

Supplemented by summaries of a selection of ESMO abstract presentations, EMJ’s Oncology eJournal provides a comprehensive summary of the 5 days in Munich…

First In-Human Study with GSK3359609, an Inducible T cell Costimulator Receptor Agonist in Patients with Advanced, Solid Tumours: Preliminary Results from INDUCE-1

Inducible T cell costimulator (ICOS), a member of the CD28/B7 receptor superfamily, is expressed on T cells after T cell receptor engagement with cognate…

Prof Ahmad Awada

Head of the Medical Oncology and Medicine Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium…

The Right Therapy Starts with the Right Test: Novel Therapeutic Approaches in Oncology Foster the Need for an Appropriate Molecular Profiling Strategy

Adding a molecular perspective to the traditional multidisciplinary management of cancer patients is substantially hampering the adoption of precision…

Preliminary Safety, Efficacy, and Pharmacokinetic and Pharmacodynamic Characterisation from GARNET, a Phase I Clinical Trial of the Anti-PD-1 Monoclonal Antibody TSR-042 in Patients with Recurrent or Advanced Microsatellite Instability-High Endometrial Cancer

At the European Society for Medical Oncology (ESMO) 2018 Congress, data from the ongoing Phase I clinical trial of the anti-programmed death…